MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
Healthcare
$1.28 +3.98%
+$0.05 today
- Market cap
- $132.16M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
52W Low $0.64High $2.37
Volume 1.67M
Average 0.95M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$34.41M
FY 2025 · Annual
Investing Cash Flow
$25.93M
FY 2025 · Annual
+274.1% YoYFinancing Cash Flow
$656,000.00
FY 2025 · Annual
-68.1% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Depreciation & Amortization | 1.42M | 2.7M | 4.57M | 4.32M | 5.14M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.96M | 0 | 13.98M | 0 | 9.21M |
| Change in Working Capital | (1.64M) | (3.21M) | 3.82M | (751K) | (6.12M) |
| Accounts Receivables | (1.71M) | (6.69M) | 7.14M | 1.23M | 1.15M |
| Inventory | (1.41M) | (3.49M) | (4.53M) | 1.36M | 575K |
| Accounts Payables | 2.09M | (149.7K) | 3.25M | (1.88M) | (3.72M) |
| Other Working Capital | (624.7K) | 7.12M | (2.04M) | (1.46M) | (4.13M) |
| Other Non-Cash Items | 664.6K | 9.3M | (6.13M) | 9.88M | 1.99M |
| Operating Cash Flow | (10.68M) | (14.78M) | (21.69M) | (27.61M) | (34.41M) |
| Capital Expenditures | (3.83M) | (18.48M) | (3.7M) | (1.65M) | (1.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (1.77M) |
| Purchases of Investments | (268.68M) | (290.94M) | (255.1M) | (150.86M) | (126.29M) |
| Sales of Investments | 77.5M | 284.6M | 313.77M | 159.44M | 155.76M |
| Other Investing Activities | 4.6K | 0 | 9K | 0 | 0 |
| Investing Cash Flow | (195.01M) | (24.82M) | 54.98M | 6.93M | 25.94M |
| Debt Repayment | (4.99M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 236.08M | 2.89M | 269K | 2.06M | 656K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.63M | 0 | 1.87M | 0 | 0 |
| Financing Cash Flow | 234.72M | 2.89M | 2.14M | 2.06M | 656K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.03M | (36.72M) | 35.44M | (18.62M) | (7.82M) |
| Free Cash Flow | (14.51M) | (33.26M) | (25.39M) | (29.26M) | (36.18M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$44.6M
+ D&A$5.1M
+ Stock-Based Comp$9.2M
+ Deferred Tax$0
- Working Capital-$6.1M
+ Other Non-Cash$2.0M
= Operating Cash Flow-$34.4M
- Capex-$1.8M
= Free Cash Flow-$36.2M
Analysis
FY2025 free cash flow is -$36.2M. FCF conversion is 81.1% of net income. Operating cash flow was -$34.4M, with capex of -$1.8M. The largest bridge item is Stock-Based Comp at $9.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13D | SC 13D filing | Nov 2, 2026 | |
| SC 13D | SC 13D filing | Oct 15, 2026 | |
| 8-K | Current report | Oct 14, 2026 |
Does MXCT generate free cash flow?
MaxCyte, Inc. (MXCT) generated -$36.18M of free cash flow in fiscal 2025.
How much operating cash flow does MXCT produce?
Operating cash flow was -$34.41M, before capital expenditures of $1.77M.
Continue the stock analysis
Jump to another research area for this company.